نتایج جستجو برای: cyp2c9 and vkorc1 polymorphisms

تعداد نتایج: 16835218  

Journal: :Clinical pharmacology and therapeutics 2008
M-S Wen Mtm Lee J-J Chen H-P Chuang L-S Lu C-H Chen T-H Lee C-T Kuo F-M Sun Y-J Chang P-L Kuan Y-F Chen M-J Charng C-Y Ray J-Y Wu Y-T Chen

Polymorphisms in CYP2C9 and VKORC1 have been shown to be associated with warfarin dose requirements and could be used to predict warfarin dose. We conducted a prospective study in which warfarin dose was prescribed based on CYP2C9 and VKORC1 polymorphisms in 108 Han-Chinese patients without prior warfarin treatments. Using the genotype-based dosing, 83% of patients reached stable, therapeutic i...

Journal: :Blood 2011
Inna Y Gong Rommel G Tirona Ute I Schwarz Natalie Crown George K Dresser Samantha Larue Nicole Langlois Alejandro Lazo-Langner Guangyong Zou Dan M Roden C Michael Stein Marc Rodger Marc Carrier Melissa Forgie Philip S Wells Richard B Kim

Single-nucleotide polymorphisms in genes that affect warfarin metabolism (cytochrome P450 2C9 gene, CYP2C9) and response (vitamin K epoxide reductase complex 1 gene, VKORC1) have an important influence on warfarin therapy, particularly during initiation; however, there is a lack of consensus regarding the optimal pharmacogenetics-based initiation strategy. We conducted a prospective cohort stud...

Journal: :Clinical chemistry 2009
Tohru Aomori Koujirou Yamamoto Atsuko Oguchi-Katayama Yuki Kawai Takefumi Ishidao Yasumasa Mitani Yasushi Kogo Alexander Lezhava Yukiyoshi Fujita Kyoko Obayashi Katsunori Nakamura Hugo Kohnke Mia Wadelius Lena Ekström Cristine Skogastierna Anders Rane Masahiko Kurabayashi Masami Murakami Paul E Cizdziel Yoshihide Hayashizaki Ryuya Horiuchi

BACKGROUND Polymorphisms of the CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) gene (CYP2C9*2, CYP2C9*3) and the VKORC1 (vitamin K epoxide reductase complex, subunit 1) gene (-1639G>A) greatly impact the maintenance dose for the drug warfarin. Prescreening patients for their genotypes before prescribing the drug facilitates a faster individualized determination of the proper mai...

2017
Rui Liu Jian Cao Qian Zhang Xin-Miao Shi Xiao-Dong Pan Ran Dong

The effects of genetic variants on warfarin dosing vary among different ethnic groups, especially in the Chinese population. The objective of this study was to recruit patients through a rigorous experimental design and to perform a comprehensive screen to identify gene polymorphisms that may influence warfarin dosing in northern Han Chinese patients with mechanical heart valve replacement. Con...

Journal: :Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2009
Srun Kuanprasert Sakchai Dettrairat Poonsub Palacajornsuk Warunee Kunachiwa Arintaya Phrommintikul

BACKGROUND Warfarin has been widely used for the prevention and treatment of thromboembolism. Warfarin therapy depends on interaction between physiological, environmental, and genetic factors. Vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) enzyme conjointly determine the warfarin maintenance dose. The prevalence of CYP2C9 and VKORC1 variants varies among ethnic groups. Th...

2015
FC Militaru SC Vesa TR Pop AD Buzoianu

RATIONALE Vitamin K antagonists (VKA), such as warfarin and acenocoumarol, are widely used for the prevention and treatment of thromboembolic diseases and they are some of the most commonly prescribed types of medications. They are characterized by narrow therapeutic indices and inter-individual or intra-individual variability in response to the treatment. OBJECTIVE to establish the influence...

2016
IS Hamadeh MH Shahin SM Lima F Oliveira L Wilson SI Khalifa TY Langaee RM Cooper‐DeHoff LH Cavallari JA Johnson

Genotype-based algorithms that include VKORC1 and CYP2C9 genotypes are less predictive of warfarin dose variability in Africans as opposed to Europeans. Polymorphisms in GGCX, FPGS, or STX1B are associated with warfarin dose requirements in African-Americans. We sought to determine if they influenced warfarin dose in European-Americans, and another African population, specifically Egyptians. We...

Journal: :Clinical medicine & research 2007
Michael D Caldwell Richard L Berg Kai Qi Zhang Ingrid Glurich John R Schmelzer Steven H Yale Humberto J Vidaillet James K Burmester

OBJECTIVES Warfarin is a commonly prescribed anticoagulant drug used to prevent thromboses that may arise as a consequence of orthopedic and vascular surgery or underlying cardiovascular disease. Warfarin is associated with a notoriously narrow therapeutic window where small variations in dosing may result in hemorrhagic or thrombotic complications. To ultimately improve dosing of warfarin, we ...

Journal: :Clinical pharmacology and therapeutics 2008
Y Caraco S Blotnick M Muszkat

Warfarin anticoagulation effect is characterized by marked variability, some of which has been attributed to CYP2C9 polymorphisms. This study prospectively examines whether a priori knowledge of CYP2C9 genotype may improve warfarin therapy. Patients were randomly assigned to receive warfarin by a validated algorithm ("control", 96 patients) or CYP2C9 genotype-adjusted algorithms ("study", 95 pa...

2011
Florentina Claudia Militaru Ioana Corina Bocşan Anca Dana Buzoianu

Inherited variants of the enzymes involved in drug metabolism, transporters, receptors may play an important role in drug response. Genotyping prior to drug administration seems to be a promising clinical approach in order to reduce the adverse effects of the drugs and to increase their efficacy. Oral anticoagulants (OAs) are drugs largely used in the prevention and treatment of thrombo-embolic...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید